{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/prescribing-information/nitrates/","result":{"pageContext":{"chapter":{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates","depth":2,"htmlHeader":"<!-- begin field c7f60e1b-d2c1-417c-abc6-0a6a76a459b4 --><h2>Nitrates</h2><!-- end field c7f60e1b-d2c1-417c-abc6-0a6a76a459b4 -->","summary":"","htmlStringContent":"<!-- begin item ebe0fc03-224a-4fd6-a8f6-22644eb10104 --><!-- end item ebe0fc03-224a-4fd6-a8f6-22644eb10104 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"483a4274-e836-5c7f-8728-1435b5f7b27b","slug":"choice-of-nitrate","fullItemName":"Choice of nitrate","depth":3,"htmlHeader":"<!-- begin field e63ec52e-17ea-4a07-93ea-23cea879ead4 --><h3>Choice of nitrate</h3><!-- end field e63ec52e-17ea-4a07-93ea-23cea879ead4 -->","summary":"","htmlStringContent":"<!-- begin item 2e33e16c-6517-4a8d-8849-228f49a3bb31 --><!-- begin field abe2d2d7-e993-4f9a-8759-60e0abbae904 --><ul><li>Short-acting, sublingual glyceryl trinitrate (GTN) should be used for immediate relief of an episode of angina, or before activities that are likely to precipitate angina.</li><li>Long-acting oral nitrates should be used regularly to decrease the frequency and severity of anginal symptoms.</li></ul><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Stable angina: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016b</a>].</p><!-- end field abe2d2d7-e993-4f9a-8759-60e0abbae904 --><!-- end item 2e33e16c-6517-4a8d-8849-228f49a3bb31 -->","subChapters":[]},{"id":"c165118f-8963-5959-9bb4-b6463cb3bbf8","slug":"dose-formulation","fullItemName":"Dose and formulation","depth":3,"htmlHeader":"<!-- begin field c2c46f46-e4af-4c7f-bb9f-51c8a7bc55b0 --><h3>Dose and formulation</h3><!-- end field c2c46f46-e4af-4c7f-bb9f-51c8a7bc55b0 -->","summary":"","htmlStringContent":"<!-- begin item b77c4b60-0133-4329-9cc3-763de638e4e7 --><!-- begin field a7848dee-41ca-449e-811d-163148d1eeea --><h4><strong>Short-acting sublingual nitrates</strong></h4><ul><li><strong>Glyceryl trinitrate tablets </strong>— 300 micrograms to 1 mg at the onset of an attack, or prior to a precipitating event. </li><li><strong>Glyceryl trinitrate spray </strong>— one or two 400 microgram metered doses sprayed under the tongue at the onset of an attack, or prior to a precipitating event.</li><li>A second dose of sublingual trinitrate can be taken after 5 minutes if the pain has not eased. <ul><li>An ambulance should be called if the pain has not eased 5 minutes after the second dose, or earlier if the pain is intensifying or the person is unwell.</li></ul></li></ul><h4><strong>Long-acting nitrates</strong></h4><ul><li><strong>Standard-release nitrate preparations: </strong>use an asymmetric dosing interval to maintain a daily nitrate-free time of 10 to 14 hours to minimize development of nitrate tolerance. <ul><li>Isosorbide mononitrate dose —10 mg twice daily, to 120 mg daily in divided doses.</li><li>Isosorbide dinitrate dose — 30-120 mg daily in divided doses. </li></ul></li><li><strong>Modified-release nitrate preparations: </strong>use a once-daily dose to maintain a nitrate-low period and thus minimize tolerance.<ul><li>Isosorbide mononitrate dose — 25-120 mg once daily. </li><li>Modified-release preparations are more expensive than standard-release preparations, but they may be useful for people who find it difficult to comply with an asymmetric dosing regimen.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">SIGN, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ACCF, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ESC, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]</p><!-- end field a7848dee-41ca-449e-811d-163148d1eeea --><!-- end item b77c4b60-0133-4329-9cc3-763de638e4e7 -->","subChapters":[]},{"id":"d4f880f9-42f7-5bf3-8343-74c24ba287c4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d394fe5c-a580-41fb-b9bc-af747918b4ee --><h3>Adverse effects</h3><!-- end field d394fe5c-a580-41fb-b9bc-af747918b4ee -->","summary":"","htmlStringContent":"<!-- begin item 4c84ccdd-617d-416a-93d7-947ce7c596f6 --><!-- begin field a48b75ca-85b8-43b0-b07f-8842dda125ca --><ul><li><strong>Transient hypotension </strong>that manifests as dizziness, weakness, and palpitations has been reported with isosorbide mononitrate. Hypotension often presents as postural hypotension occurring shortly after drug administration.</li><li><strong>Headache </strong>— this is very common at the start of treatment, but usually subsides after 1–2 weeks.<ul><li>To minimize the risk of headache, start at a low dose (for example 10 mg twice a day) and titrate up.</li><li>Glyceryl trinitrate (GTN) may precipitate a migraine headache in people with a history of migraine.</li></ul></li><li><strong>Burning, stinging, or tingling of the mouth </strong>is experienced by some people taking sublingual GTN tablets.<ul><li>If this occurs, lower strength GTN tablets can be used, or a GTN sublingual spray.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Micromedex, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016c</a>]</p><!-- end field a48b75ca-85b8-43b0-b07f-8842dda125ca --><!-- end item 4c84ccdd-617d-416a-93d7-947ce7c596f6 -->","subChapters":[]},{"id":"2dc06865-7358-5cc1-bbf9-3880f19d0c60","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field d5b09068-1172-4963-aaf9-bd60898db491 --><h3>Cautions and contraindications</h3><!-- end field d5b09068-1172-4963-aaf9-bd60898db491 -->","summary":"","htmlStringContent":"<!-- begin item 37673905-3bdd-4234-9da1-51b4db4e425c --><!-- begin field d078f937-f5bf-4f70-bbfe-eea37b67bd8e --><ul><li>Nitrates should not be used in people with:<ul><li>Acute myocardial infarction (MI) with low filling pressure, acute circulatory failure, (shock, vascular collapse), or very low blood pressure.</li><li>Hypertrophic obstructive cardiomyopathy (HOCM), constrictive pericarditis, cardiac tamponade, low cardiac filling pressures, or aortic/mitral valve stenosis. </li><li>Diseases associated with a raised intra-cranial pressure (for example following a head trauma, including cerebral haemorrhage).</li><li>Severe anaemia.</li><li>Closed angle glaucoma.</li><li>Severe hypotension, or hypovolaemia.</li></ul></li><li>Nitrates should be used with caution in people with:<ul><li>A recent history of M low filling pressures.</li><li>Hypothyroidism. </li><li>Hypothermia,</li><li>Malnutrition.</li><li>Severe liver disease.</li><li>Chronic kidney disease.</li><li>Impaired left ventricular function.</li><li>Closed-angle glaucoma, which can be precipitated by nitrates. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Micromedex, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016c</a>]</p><!-- end field d078f937-f5bf-4f70-bbfe-eea37b67bd8e --><!-- end item 37673905-3bdd-4234-9da1-51b4db4e425c -->","subChapters":[]},{"id":"00dc0367-7e8f-51db-8a94-a7ca499a601d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3221e598-73e3-49cd-a115-aed650fbcdd5 --><h3>Drug interactions</h3><!-- end field 3221e598-73e3-49cd-a115-aed650fbcdd5 -->","summary":"","htmlStringContent":"<!-- begin item 4a22eff5-dfdc-41fb-848b-88a8de3b4482 --><!-- begin field 80f4f7ed-4aff-4ad9-87b0-37996aa2ab19 --><ul><li><strong>Phosphodiesterase inhibitors (sildenafil, tadalafil, and vardenafil) </strong>— concurrent us with nitrates is contraindicated, as this can produce excessive hypotension, and may precipitate myocardial infarction.<ul><li>A nitrate should not be taken for at least 24 hours after the last dose of sildenafil or vardenafil, and for at least 48 hours after the last dose of tadalafil.</li><li>A phosphodiesterase inhibitor should not be taken for at least 24 hours after the last dose of a nitrate.</li><li>Advise people with angina who are taking a phosphodiesterase inhibitor that they must not use glyceryl trinitrate (GTN) if they have an episode of angina during sexual intercourse. Advise them to stop sexual activity and, if their pain does not resolve within 10 minutes, they should call 999 for an ambulance.</li></ul></li><li><strong>Soluble guanylate cyclase stimulator, riociguat </strong>— this potentiates the hypotensive effect of nitrates. Concomitant use is contraindicated.  </li><li><strong>Antihypertensives </strong>(for example beta-blockers, calcium channel blockers, vasodilators, and angiotensin II receptor antagonists) — these potentiate the hypotensive effects of nitrates.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ESC, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016c</a>]</p><!-- end field 80f4f7ed-4aff-4ad9-87b0-37996aa2ab19 --><!-- end item 4a22eff5-dfdc-41fb-848b-88a8de3b4482 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}